Cherry juice may shield nerves during chemo

NCT ID NCT06268665

First seen Mar 10, 2026 · Last updated Jun 20, 2026 · Updated 12 times

Summary

This study tests whether drinking tart cherry juice can prevent nerve damage caused by the chemotherapy drug paclitaxel in people with breast or ovarian cancer. Participants will drink either a high or low dose of the juice daily during their 12-week chemotherapy. The goal is to see if the juice reduces numbness, tingling, and pain in the hands and feet.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95827, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tart cherry juice

What this could lead to

If it works, this could offer a simple, natural way to prevent painful nerve damage from chemotherapy, improving quality of life for cancer patients.

What could go wrong

This is a small, early-phase trial with only 86 participants, so results may not apply to everyone. The juice might not prevent nerve damage, and high doses could cause side effects like stomach upset.

Conditions

The condition(s) this trial relates to.

breast neoplasm invasive breast carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.